Natalie K. Boyd
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Natalie K. Boyd has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Cindy L. Zoellner
Parkland Health and Hospital System, Dallas, Texas, USA
1 shared publicationKavita P. Bhavan
Parkland Health and Hospital System, Dallas, Texas, USA
1 shared publicationMark A. Swancutt
Parkland Health and Hospital System, Dallas, Texas, USA
1 shared publication
Latest Publications
- 1 November 2012
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (11) , 6001-6002
Utilization of Omeprazole To Augment Subtherapeutic Voriconazole Concentrations for Treatment of Aspergillus Infections
Voriconazole is the preferred antifungal agent for Aspergillus infections. Therapeutic drug monitoring is recommended to achieve target concentrations and prevent toxicity. However, variable pharmacokinetics, cytochrome P450 polymorphisms, and extensive drug-drug interactions can contribute to subtherapeutic concentrations. We report a voriconazole “boosting” effect of omeprazole to achieve target concentrations for the treatment of Aspergillus in a patient who had persistently subtherapeutic trough concentrations.
- 1 November 2012
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (11) , 6001-6002
Utilization of Omeprazole To Augment Subtherapeutic Voriconazole Concentrations for Treatment of Aspergillus Infections
Voriconazole is the preferred antifungal agent for Aspergillus infections. Therapeutic drug monitoring is recommended to achieve target concentrations and prevent toxicity. However, variable pharmacokinetics, cytochrome P450 polymorphisms, and extensive drug-drug interactions can contribute to subtherapeutic concentrations. We report a voriconazole “boosting” effect of omeprazole to achieve target concentrations for the treatment of Aspergillus in a patient who had persistently subtherapeutic trough concentrations.